Skip to main navigation

Utility Menu

  • Patients
  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English

Utility Menu

  • Patients
  • Investors
  • Newsroom
  • Contact Us

Regional Navigation

  • global sites
    Global Sites
    • Switzerland flag
      Switzerland
      • Deutsch
      • English
      • Français
      • Italiano
    • UK flag
      UK
      • English
    • global sites
      United States
      • English
Home

Social Links

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
  • Our Science
    • RNA Platform
    • Gene Therapy
    • Manufacturing
    • Strategic Partnerships
    • Investigator-Initiated Studies
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

  • Home
  • Investor Relations
  • Featured IR Home

IR Menu

IR Home
Press Releases
Events & Presentations
Corporate Governance
Stock Information
SEC Filings
Analyst Coverage
Information Request
FAQs

Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs

  • Read more about Phase 1/2 Preliminary Data Readout for DM1 and FSHD Programs

2026 MDA Clinical & Scientific Conference

  • Read more about 2026 MDA Clinical & Scientific Conference

TD Cowen 46th Annual Health Care Conference

  • Read more about TD Cowen 46th Annual Health Care Conference

Sarepta Therapeutics Fourth Quarter 2025 Earnings Call

  • Read more about Sarepta Therapeutics Fourth Quarter 2025 Earnings Call

Sarepta EMBARK Study 3 Year Topline Results

  • Read more about Sarepta EMBARK Study 3 Year Topline Results

Sarepta Therapeutics 2026 JPMorgan Conference Presentation

  • Read more about Sarepta Therapeutics 2026 JPMorgan Conference Presentation

2026 JP Morgan Healthcare Conference

  • Read more about 2026 JP Morgan Healthcare Conference

Sarepta Therapeutics Third Quarter 2025 Earnings Call

  • Read more about Sarepta Therapeutics Third Quarter 2025 Earnings Call

30th Annual International Congress of the World Muscle Society - 2025

  • Read more about 30th Annual International Congress of the World Muscle Society - 2025

Analyst Q&A Regarding LGMD Programs

  • Read more about Analyst Q&A Regarding LGMD Programs

Pagination

  • Page 1
  • Next page ››
Subscribe to Featured IR Home

Toolkit

Print Page | Email Alerts | RSS Feeds | Contacts

Follow Us On Social

  • Twitter
  • LinkedIn
  • Instagram
  • Facebook

Main navigation

  • Our Disease Areas
    • Duchenne Muscular Dystrophy
    • Limb-girdle Muscular Dystrophy
  • Our Science
    • RNA Platform
    • Gene Therapy
    • Manufacturing
    • Strategic Partnerships
    • Investigator-Initiated Studies
  • Our Products & Pipeline
    • Products
    • Pipeline
    • Clinical Trials
    • Treatment Access
  • About Us
    • Leadership
    • Patient Affairs
    • Corporate Responsibility
    • Grants & Giving
    • Global Locations
    • Contact Us
  • Join Us
    • Career Opportunities

©2026 Sarepta Therapeutics, Inc. All rights reserved.

Footer Utility Nav

  • Privacy Policy
  • Terms of Use
  • Data Privacy Framework Policy